CFTR and cystic fibrosis: The triple combination of CFTR modulators elexacaftor/tezacaftor/ivacaftor (ETI) was registered with the U.S. Food and Drug Administration (FDA) in 2019 for people with CF who carry at least one copy of the variant F508del.